2017
Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, Sprenkle PC. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingSignificant prostate cancerProstate cancerNegative predictive valueMagnetic resonance imagingSystematic TRUSNegative mpMRIProstate biopsyNegative multiparametric magnetic resonance imagingPredictive valueResonance imagingClinically Significant Prostate CancerDynamic contrast enhancement sequencesTemplate mapping biopsyPrior negative biopsySystematic prostate biopsyOverall cancer detectionProstate-specific antigenTemplate prostate biopsyProstate cancer detectionDiffusion-weighted imagingCancer detectionBiopsy naïveMapping biopsyProstate volume
2016
MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsy
2015
NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence
Manda K, Tripathi P, Hsi A, Ning J, Ruzinova M, Liapis H, Bailey M, Zhang H, Maher C, Humphrey P, Andriole G, Ding L, You Z, Chen F. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. Oncogene 2015, 35: 3282-3292. PMID: 26477312, PMCID: PMC5012433, DOI: 10.1038/onc.2015.389.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCell LineCell Line, TumorCell ProliferationCell Transformation, NeoplasticCellular SenescenceCytokinesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMice, KnockoutMice, NudeMice, TransgenicNFATC Transcription FactorsProstateProstatic NeoplasmsPTEN PhosphohydrolaseReverse Transcriptase Polymerase Chain ReactionTransplantation, HomologousTumor Cells, CulturedTumor MicroenvironmentConceptsProstate tumorigenesisHuman PCaNFATc1 activationNon-tumorigenic prostate cellsActivated T cells c1Cultured PCa cellsT cells c1Cellular senescenceRole of NFATc1Number of cytokinesActivation of NFATc1Proinflammatory cytokinesPCa cellsProstate cancerProstatic adenocarcinomaLuminal epitheliumMouse prostateCells c1Normal prostateOncogenic roleOncogene c-mycProstate tissueProstate cellsSoluble factorsNuclear factor
2006
Immunohistochemistry in the diagnosis of minimal prostate cancer
Hameed O, Humphrey P. Immunohistochemistry in the diagnosis of minimal prostate cancer. Diagnostic Histopathology 2006, 12: 279-291. DOI: 10.1016/j.cdip.2006.05.003.Peer-Reviewed Original ResearchBasal cell markersProstatic adenocarcinomaProstate needle biopsy tissueCell markersMinimal prostate cancerNeedle biopsy tissueEosin-stained sectionsCytokeratin 5/6Invasive carcinomaProstatic lesionsProstate cancerDiagnostic yieldBenign mimickersBiopsy tissueImmunohistochemistryConcurrent useAdenocarcinomaDiagnosisBasal cellsAntibodiesMarkers
2004
EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
ANDRIOLE G, HUMPHREY P, RAY P, GLEAVE M, TRACHTENBERG J, THOMAS L, LAZIER C, RITTMASTER R. EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER. Journal Of Urology 2004, 172: 915-919. PMID: 15310997, DOI: 10.1097/01.ju.0000136430.37245.b9.Peer-Reviewed Original ResearchConceptsProstate cancerMicrovessel densityDutasteride treatmentIntraprostatic dihydrotestosteroneTumor regressionDual 5α-Reductase Inhibitor DutasterideShort-term pilot studyDays of placeboEffect of dutasterideIntraprostatic androgen levelsT2 prostate cancerDegree of atrophyProstate cancer treatmentShort-term treatmentProstate cancer tissuesIndex of apoptosisRadical prostatectomyEarly treatmentAndrogen levelsDutasterideCancer tissuesResected tissuesDHT formationDihydrotestosteroneType 1Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480
Humphrey P, Halabi S, Picus J, Vogelzang N, Small E, Kantoff P. Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. Journal Of Clinical Oncology 2004, 22: 9613-9613. DOI: 10.1200/jco.2004.22.14_suppl.9613.Peer-Reviewed Original ResearchScatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480
Humphrey P, Halabi S, Picus J, Vogelzang N, Small E, Kantoff P. Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. Journal Of Clinical Oncology 2004, 22: 9613-9613. DOI: 10.1200/jco.2004.22.90140.9613.Peer-Reviewed Original Research
2001
The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer
Vollmer R, Humphrey P. The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer. American Journal Of Clinical Pathology 2001, 116: 864-870. PMID: 11764075, DOI: 10.1309/7mq7-mwar-4w8a-r75f.Peer-Reviewed Original ResearchConceptsElevated PSA levelsEarly deathPSA levelsRadical prostatectomyProstate cancerPathology observationsGleason grade 5Overall good prognosisTime of prostatectomyPostoperative levelsPSA failureStudy patientsBetter prognosisProgressive tumorsPrognostic categoriesPercentage carcinomaProstatectomySubsequent outcomesLower hazardDeathSurgeryHigher hazardCancerMenPSAFrequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma
Abdulkadir S, Carbone J, Naughton C, Humphrey P, Catalona W, Milbrandt J. Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Human Pathology 2001, 32: 935-939. PMID: 11567222, DOI: 10.1053/hupa.2001.27102.Peer-Reviewed Original ResearchConceptsHuman prostate cancerHuman prostate carcinomaProstate cancerProstate carcinomaProstatic intraepithelial neoplasia lesionsIntraepithelial neoplasia lesionsProstate carcinoma specimensExpression of Nab2Prostate tumor suppressorNeoplasia lesionsTumor gradeCarcinoma specimensProstate tumorigenesisTumor progressionTranscription factor EGR1Protein expressionEarly lossEGR1 levelsCarcinomaTumorigenic processCancerTumor suppressorSame stimuliEGR1Transcriptional activitySCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER
NAUGHTON M, PICUS J, ZHU X, CATALONA W, VOLLMER R, HUMPHREY P. SCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. Journal Of Urology 2001, 165: 1325-1328. PMID: 11257710, DOI: 10.1016/s0022-5347(01)69893-8.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseHepatocyte growth factorPatient ageSerum levelsNegative sextant prostate biopsiesProstate-specific antigen levelHuman prostate cancer cell linesAvailable enzyme-linked immunosorbentSextant prostate biopsySpecific antigen levelsNegative sextant biopsiesProstate cancer cell linesSera of patientsImportant serum markerLogistic regression analysisEnzyme-linked immunosorbentCancer cell linesLocalized cancerRadiographic evidenceSerum markersAntigen levelsSextant biopsyProstate biopsySCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER
NAUGHTON M, PICUS J, ZHU X, CATALONA W, VOLLMER R, HUMPHREY P. SCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. Journal Of Urology 2001, 165: 1325-1328. DOI: 10.1097/00005392-200104000-00078.Peer-Reviewed Original ResearchMetastatic prostate cancerProstate cancerMetastatic diseaseHepatocyte growth factorPatient ageSerum levelsNegative sextant prostate biopsiesProstate-specific antigen levelHuman prostate cancer cell linesAvailable enzyme-linked immunosorbentSextant prostate biopsySpecific antigen levelsNegative sextant biopsiesProstate cancer cell linesSera of patientsMethods Serum samplesImportant serum markerLogistic regression analysisEnzyme-linked immunosorbentCancer cell linesLocalized cancerRadiographic evidenceSerum markersAntigen levelsSextant biopsyImpaired prostate tumorigenesis in Egr1-deficient mice
Abdulkadir S, Qu Z, Garabedian E, Song S, Peters T, Svaren J, Carbone J, Naughton C, Catalona W, Ackerman J, Gordon J, Humphrey P, Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nature Medicine 2001, 7: 101-107. PMID: 11135623, DOI: 10.1038/83231.Peer-Reviewed Original ResearchConceptsEarly growth response protein 1Prostate cancerTumor progressionProstatic intra-epithelial neoplasiaEgr1 deficiencyIntra-epithelial neoplasiaHigh-resolution magnetic resonance imagingTransgenic mouse modelHuman prostate cancerTumor growth rateEgr1-deficient miceMagnetic resonance imagingProstate tumor progressionMouse modelProstate tumorigenesisSurvival analysisResonance imagingCarcinomaTumor developmentProtein 1ProgressionCancerMiceDeficiencyEGR1
1998
A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
Garabedian E, Humphrey P, Gordon J. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 15382-15387. PMID: 9860977, PMCID: PMC28051, DOI: 10.1073/pnas.95.26.15382.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstatic intraepithelial neoplasiaTransgenic mouse modelProstate cancerIntraepithelial neoplasiaMouse modelNeuroendocrine cellsHuman prostate cancerNeuroendocrine cell lineagesWeeks of ageNeuroendocrine differentiationSimian virus 40 T antigenLocal invasionMouse prostateCancerNeoplasiaProstateWeeksT antigenCell lineagesTransgene expressionMultiple pedigreesCellsMetastasisAndrogensClinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study
Naughton C, Smith D, Humphrey P, Catalona W, Keetch D. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998, 52: 808-813. PMID: 9801104, DOI: 10.1016/s0090-4295(98)00344-6.Peer-Reviewed Original ResearchConceptsProstate cancerBiopsy coresCore biopsySextant core biopsiesProstate volumeTotal prostate-specific antigen valuesProstate-specific antigen valuesMore biopsy coresMore biopsy sessionsPathologic tumor characteristicsPathologic tumor featuresSix-core biopsyTotal biopsy coresTRUS prostate volumeNegative prostate biopsyClinical prostate cancerMore biopsy samplesProstate cancer detectionPSA densityProspective trialInitial biopsyPathologic characteristicsProstatic volumeSerum tPSATumor characteristicsPercentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population
Arcangeli C, Humphrey P, Smith D, Harmon T, Shepherd D, Keetch D, Catalona W. Percentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population. Journal Of Urology 1998, 160: 1580-1581. DOI: 10.1016/s0022-5347(01)62623-5.Peer-Reviewed Original ResearchPercentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population
Arcangeli C, Humphrey P, Smith D, Harmon T, Shepherd D, Keetch D, Catalona W. Percentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population. Journal Of Urology 1998, 160: 1580-1581.. DOI: 10.1097/00005392-199810000-00125.Peer-Reviewed Original ResearchTHE EFFECT OF PROSTATE VOLUME, AGE, TOTAL PROSTATE SPECIFIC ANTIGEN LEVEL AND ACUTE INFLAMMATION ON THE PERCENTAGE OF FREE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITHOUT CLINICALLY DETECTABLE PROSTATE CANCER
ORNSTEIN D, SMITH D, HUMPHREY P, CATALONA W. THE EFFECT OF PROSTATE VOLUME, AGE, TOTAL PROSTATE SPECIFIC ANTIGEN LEVEL AND ACUTE INFLAMMATION ON THE PERCENTAGE OF FREE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITHOUT CLINICALLY DETECTABLE PROSTATE CANCER. Journal Of Urology 1998, 159: 1234-1237. PMID: 9507843, DOI: 10.1016/s0022-5347(01)63570-5.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelTotal PSA levelsSpecific antigen levelsDetectable prostate cancerSerum prostate-specific antigen levelFree PSA levelsPercent free PSAPSA levelsProstate volumeAcute inflammationAntigen levelsProstate cancerFree PSAFree Serum Prostate Specific Antigen LevelsTotal serum prostate-specific antigen (PSA) levelsTotal prostate-specific antigen levelsFree serum PSA levelsMean percent free PSAPercent free PSA levelsProstate cancer screening programsFree serum PSASerum PSA levelsLarge prostate glandsCancer screening programsInfluence of agePercentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population fn1fn1This study was supported in part by a grant from Hybritech Incorporated, San Diego, California.
Arcangeli C, Humphrey P, Smith D, Harmon T, Shepherd D, Keetch D, Catalona W. Percentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population fn1fn1This study was supported in part by a grant from Hybritech Incorporated, San Diego, California. Urology 1998, 51: 558-565. PMID: 9586607, DOI: 10.1016/s0090-4295(98)00035-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate cancerPathologic featuresFree serum prostate-specific antigenSerum prostate-specific antigenFree prostate-specific antigenCancerous surgical marginsProstate cancer screeningPercentage of cancerRadical prostatectomy specimenHarmless cancersPreoperative predictorsWatchful waitingSurgical marginsCapsular penetrationProstatic capsuleGleason scoreCancer screeningRadical prostatectomyProstatectomy specimenTumor volumeFPSAClinical practiceCancerScreening evaluationTHE EFFECT OF PROSTATE VOLUME, AGE, TOTAL PROSTATE SPECIFIC ANTIGEN LEVEL AND ACUTE INFLAMMATION ON THE PERCENTAGE OF FREE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITHOUT CLINICALLY DETECTABLE PROSTATE CANCER
ORNSTEIN D, SMITH D, HUMPHREY P, CATALONA W. THE EFFECT OF PROSTATE VOLUME, AGE, TOTAL PROSTATE SPECIFIC ANTIGEN LEVEL AND ACUTE INFLAMMATION ON THE PERCENTAGE OF FREE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITHOUT CLINICALLY DETECTABLE PROSTATE CANCER. Journal Of Urology 1998, 159: 1234-1237.. DOI: 10.1097/00005392-199804000-00043.Peer-Reviewed Original ResearchProstate-specific antigen levelTotal PSA levelsSpecific antigen levelsDetectable prostate cancerSerum prostate-specific antigen levelFree PSA levelsPercent free PSAPSA levelsProstate volumeAcute inflammationAntigen levelsProstate cancerFree PSAFree Serum Prostate Specific Antigen LevelsTotal serum prostate-specific antigen (PSA) levelsTotal prostate-specific antigen levelsFree serum PSA levelsMean percent free PSAPercent free PSA levelsProstate cancer screening programsFree serum PSASerum PSA levelsLarge prostate glandsCancer screening programsInfluence of age
1996
Clinical and Pathological Features of Hereditary Prostate Cancer
Keetch D, Humphrey P, Smith D, Stahl D, Catalona W. Clinical and Pathological Features of Hereditary Prostate Cancer. Journal Of Urology 1996, 155: 1841-1843. PMID: 8618269, DOI: 10.1016/s0022-5347(01)66024-5.Peer-Reviewed Original ResearchConceptsHereditary prostate cancerSporadic prostate cancerProstate cancerPathological featuresGleason scoreSerum prostate-specific antigen (PSA) concentrationProstate-specific antigen concentrationDate of surgeryMean Gleason scoreSpecific antigen concentrationLow Gleason scoreHereditary diseaseRadical prostatectomy specimensFamily historyPathological differencesProstatectomy specimensMedian percentageSporadic carcinomasCancerAntigen concentrationSporadic cancersCarcinomaMenDiseaseScores